Trial Endpoints for Aspergillus and Rare Molds: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology.
Researchers
Martin Hoenigl, George R Thompson, Jessica S Little, Bart J Rijnders, Ritesh Agarwal, Oliver A Cornely, Jean-Pierre Gangneux, Dimitrios P Kontoyiannis, Cornelia Lass-Flörl, Johan Maertens, Marcio Nucci, Peter G Pappas, Matthew Goon, Emmanuel Roilides, Thomas J Walsh, Carolynn T Jones, Gerald McGwin, Thomas F Patterson, Luis Ostrosky-Zeichner, Monica A Slavin
Abstract
Invasive mold disease (IMD) remains a substantial cause of patient morbidity and mortality. Aspergillosis and mucormycosis remain the predominant infections encountered, although rare molds continue to emerge as important pathogens. Improvement in patient outcomes has been the result of progress in risk stratification, diagnostics, supportive care, antifungal therapy, and/or prophylaxis, yet substantial challenges remain, requiring the development of novel treatment strategies. Clinical trials evaluating treatment response are currently based on consensus criteria published in 2008. However, advances in clinical mycology and the broadening variety of mold diseases in clinical trials necessitate a revision of these criteria to ensure that adjudication of patient outcomes accurately captures responses to therapeutic intervention. To tackle this task, an international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened. The panel produced updated consensus guidance for assessing treatment responses and defining study outcomes in clinical trials of IMD in both adults and children. Along with guidance, potential pitfalls in assessing outcome, such as discordant clinical, radiologic, and/or mycologic data and areas for future research are discussed.Source: PubMed (PMID: 43043132)View Original on PubMed